

S 2476

Expanding Access to Low Cost Generic Drugs Act

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 28, 2018

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 28, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/2476>

Sponsor

Name: Sen. Smith, Tina [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 28, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 3411	Related bill	Sep 5, 2018: Read twice and referred to the Committee on Finance.
115 HR 1776	Related bill	Apr 5, 2017: Referred to the Subcommittee on Health.
115 S 771	Related bill	Mar 29, 2017: Read twice and referred to the Committee on Finance.

Summary (as of Feb 28, 2018)

Expanding Access to Low Cost Generic Drugs Act

This bill amends the Federal Food, Drug, and Cosmetic Act to disqualify from receiving market exclusivity a generic drug manufacturer who enters into an agreement with the patent holder for a brand name drug to delay getting the generic drug approved or to delay marketing it.

Actions Timeline

- **Feb 28, 2018:** Introduced in Senate
- **Feb 28, 2018:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.